Consistently, we found that NPC patients with high KIF18B expression had significantly higher IC50 values for gemcitabine, oxaliplatin and 5-fluorouracil than those with low KIF18B expression (Figures 10C, D). The gene discussed is KIF18B; the disease is nasopharyngeal carcinoma.